Credit Suisse’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $1.94M | Sell |
103,406
-9,312
| -8% | -$215K | ﹤0.01% | 1872 |
|
|
2023
Q4 | $2.44M | Sell |
112,718
-1,205
| -1% | -$23.9K | ﹤0.01% | 1767 |
|
|
2023
Q3 | $2.34M | Buy |
113,923
+21,136
| +23% | +$610K | ﹤0.01% | 1727 |
|
|
2023
Q2 | $4.36M | Sell |
92,787
-3,448
| -4% | -$172K | ﹤0.01% | 1428 |
|
|
2023
Q1 | $4.04M | Sell |
96,235
-5,014
| -5% | -$216K | ﹤0.01% | 1448 |
|
|
2022
Q4 | $3.86M | Buy |
101,249
+4,042
| +4% | +$154K | ﹤0.01% | 1463 |
|
|
2022
Q3 | $3.81M | Buy |
97,207
+191
| +0.2% | +$7.38K | ﹤0.01% | 1426 |
|
|
2022
Q2 | $3.13M | Buy |
97,016
+3,708
| +4% | +$124K | ﹤0.01% | 1606 |
|
|
2022
Q1 | $3.09M | Buy |
93,308
+12,361
| +15% | +$465K | ﹤0.01% | 1780 |
|
|
2021
Q4 | $3.44M | Buy |
80,947
+8,005
| +11% | +$335K | ﹤0.01% | 2330 |
|
|
2021
Q3 | $3.23M | Buy |
72,942
+1,456
| +2% | +$66.8K | ﹤0.01% | 2419 |
|
|
2021
Q2 | $4.06M | Buy |
71,486
+18,855
| +36% | +$1.33M | ﹤0.01% | 2256 |
|
|
2021
Q1 | $3.94M | Sell |
52,631
-12,315
| -19% | -$1.01M | ﹤0.01% | 2275 |
|
|
2020
Q4 | $5.62M | Sell |
64,946
-5,303
| -8% | -$391K | ﹤0.01% | 2002 |
|
|
2020
Q3 | $4.29M | Sell |
70,249
-44,859
| -39% | -$2.27M | ﹤0.01% | 1888 |
|
|
2020
Q2 | $4.79M | Buy |
115,108
+27,857
| +32% | +$1.01M | ﹤0.01% | 1735 |
|
|
2020
Q1 | $2.5M | Buy |
87,251
+24,517
| +39% | +$1.42M | ﹤0.01% | 1981 |
|
|
2019
Q4 | $4.53M | Buy |
62,734
+30,042
| +92% | +$3.7M | ﹤0.01% | 1952 |
|
|
2019
Q3 | $4.59M | Sell |
32,692
-11,053
| -25% | -$1.85M | ﹤0.01% | 1818 |
|
|
2019
Q2 | $8.01M | Buy |
43,745
+14,872
| +52% | +$2.54M | 0.01% | 1447 |
|
|
2019
Q1 | $4.59M | Sell |
28,873
-85
| -0.3% | -$12.3K | ﹤0.01% | 1770 |
|
|
2018
Q4 | $2.77M | Sell |
28,958
-3,751
| -11% | -$429K | ﹤0.01% | 1999 |
|
|
2018
Q3 | $4.62M | Sell |
32,709
-1,919
| -6% | -$296K | ﹤0.01% | 1751 |
|
|
2018
Q2 | $5.42M | Sell |
34,628
-17,772
| -34% | -$2.79M | 0.01% | 1672 |
|
|
2018
Q1 | $8.44M | Buy |
52,400
+10,493
| +25% | +$1.78M | 0.01% | 1346 |
|
|
2017
Q4 | $6.9M | Sell |
41,907
-36,070
| -46% | -$3.5M | 0.01% | 1537 |
|
|
2017
Q3 | $4.86M | Buy |
77,977
+14,630
| +23% | +$1.15M | ﹤0.01% | 1783 |
|
|
2017
Q2 | $5.04M | Sell |
63,347
-24,142
| -28% | -$1.75M | ﹤0.01% | 1624 |
|
|
2017
Q1 | $6.22M | Sell |
87,489
-33,196
| -28% | -$1.94M | 0.01% | 1499 |
|
|
2016
Q4 | $6.16M | Buy |
120,685
+55,633
| +86% | +$2.62M | 0.01% | 1505 |
|
|
2016
Q3 | $3M | Buy |
65,052
+30,269
| +87% | +$1.23M | ﹤0.01% | 2077 |
|
|
2016
Q2 | $1.05M | Sell |
34,783
-1,618
| -4% | -$54K | ﹤0.01% | 2878 |
|
|
2016
Q1 | $1.17M | Buy |
36,401
+29,736
| +446% | +$1.05M | ﹤0.01% | 2606 |
|
|
2015
Q4 | $388K | Sell |
6,665
-9,097
| -58% | -$451K | ﹤0.01% | 3544 |
|
|
2015
Q3 | $666K | Sell |
15,762
-26,832
| -63% | -$1.65M | ﹤0.01% | 3180 |
|
|
2015
Q2 | $3.11M | Buy |
42,594
+21,810
| +105% | +$1.4M | ﹤0.01% | 2177 |
|
|
2015
Q1 | $1.04M | Buy |
20,784
+10,299
| +98% | +$443K | ﹤0.01% | 2934 |
|
|
2014
Q4 | $383K | Buy |
+10,485
| New | +$391K | ﹤0.01% | 3899 |
|
Other funds holding SAGE
RI
BG
Credit Suisse's SAGE Position: Q1 2024 in Review
Credit Suisse reduced its Sage Therapeutics (SAGE) stake by 8.3% in Q1 2024, selling an estimated $215K and leaving 103,406 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1872.
Credit Suisse first reported a position in SAGE in Q4 2014 and has held it in 38 quarters since. The position peaked at $8.44M in Q1 2018. 205 funds tracked by Wall St. Rank hold SAGE as of Q1 2024.
- Credit Suisse held 103,406 shares of Sage Therapeutics worth $1.94M as of Q1 2024.
- Credit Suisse sold 9,312 Sage Therapeutics shares in Q1 2024, an estimated $215K.
- Sage Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1872 holding.
- Credit Suisse first reported a position in Sage Therapeutics in Q4 2014 and has held it in 38 quarters since.
- Credit Suisse's Sage Therapeutics position peaked at $8.44M in Q1 2018.
- 205 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.